N,N-diethyl-2-[4-(phenylmethyl) phenoxy] ethanamine (DPPE; tesmilifene), a chemopotentiating agent with hormetic effects on DNA synthesis in vitro, may improve survival in patients with metastatic breast cancer

Human and Experimental Toxicology

Volumn 27, Issue 2, 2008, Pages 143-147

  Brandes, Lorne J ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Doxorubicin; Experimental tumors; Horemetic effects; Tesenilifene

Indexed keywords

ARACHIDONIC ACID; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 3A4; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; ETOPOSIDE; FLUOROURACIL; GLYCOPROTEIN P; HISTAMINE; HISTIDINOL; HISTIDINOL DEHYDROGENASE; HYDROXYICOSATETRAENOIC ACID; IFOSFAMIDE; PACLITAXEL; PROSTACYCLIN; TAMOXIFEN; TESMILIFENE; TRASTUZUMAB; VINCA ALKALOID; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; DIPHENYL ETHER DERIVATIVE; DNA; N,N DIETHYL 2 ((4 PHENYLMETHYL)PHENOXY)ETHANAMINE; N,N-DIETHYL-2-((4-PHENYLMETHYL)PHENOXY)ETHANAMINE; PHARMACEUTICAL VEHICLES AND ADDITIVES;

ADJUVANT THERAPY; ARACHIDONIC ACID METABOLISM; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CELL PROLIFERATION; CELL PROTECTION; CELL STIMULATION; CELL STRAIN MCF 7; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONCENTRATION (PARAMETERS); CYTOTOXICITY; DISEASE FREE SURVIVAL; DNA SYNTHESIS; DRUG BINDING; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SENSITIZATION; ESTROGEN BINDING; EXPERIMENTAL NEOPLASM; EXPERIMENTAL RAT; FATTY ACID METABOLISM; HORMESIS; HUMAN; INTESTINE; LEUKEMIA L 5178 Y; METASTASIS; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH; ADENOCARCINOMA; ANIMAL; ARTICLE; BIOSYNTHESIS; BREAST TUMOR; CELL CULTURE; DOSE RESPONSE; FEMALE; MORTALITY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; SURVIVAL RATE;

RODENTIA;

ADENOCARCINOMA; ADJUVANTS, PHARMACEUTIC; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; PHENYL ETHERS; PLATELET AGGREGATION INHIBITORS; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 48249088946     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1177/0960327108090751     Document Type: Review

References (38)

1. Chabner BA, Roberts TG Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer 2005 ; 5: 65-72.
2. Buzdar AU Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. Oncologist 2003 ; 8: 335-41.
3. Kaklamani VG, Gradishar WJ Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer ? Clin Breast Cancer 2003 ; 4 (Suppl 1). S26-33.
4. Nowak AK, Wilcken NR, Stockler MR, Hamilton A., Ghersi D. Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. Lancet Oncol 2004 ; 5: 372-80.
5. Zhou BP, Li Y., Hung MC HER-2/Neu signalling and therapeutic approaches in breast cancer. Breast Dis 2002 ; 15: 13-24.
6. Baselga J. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology 2001 ; 61 (Suppl 2). 14-21.
7. Reyno L., Seymour L., Tu D., et al. Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. J Clin Oncol 2004 ; 22: 269-76.
8. Brandes LJ, Bracken SP The intracellular histamine antagonist, N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine. HCl may potentiate doxorubicin in the treatment of metastatic breast cancer: Results of a pilot study. Breast Cancer Res Treat 1998 ; 49: 61-8.
9. Khoo K., Brandes LJ, Reyno L. et al. Phase II trial of N,N-diethyl-2-[4-(phenylmethyl) phenoxy] ethanamine. HCl and doxorubicin chemotherapy in metastatic breast cancer: A National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1999 ; 17: 3431-7.
10. Chevallier B., Mosseri V., Dauce JP, Bastit P., Julien JP, Asselain B. A prognostic score in histological node negative breast cancer. Br J Cancer 1990 ; 61: 436-40.
11. Thomas H., Coley HM Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003 ; 10: 159-65.
12. Brandes LJ, Hermonat MW A diphenylmethane derivative specific for the antiestrogen binding site found in rat liver microsomes. Biochem Biophys Res Commun 1984 ; 123: 724-8.
13. Sutherland RL, Murphy LC, Foo MS, Green MD, Whybourne AM, Krozowski ZS High affinity antiestrogen binding site distinct from the estrogen receptor. Nature 1980: 288: 273-5.
14. Watts CK, Sutherland RL High affinity specific antiestrogen binding sites are concentrated in rough microsomal membranes of rat liver. Biochem Biophys Res Commun 1984 ; 120: 109-15.
15. Brandes LJ, Hogg GR Study of the in vivo antiestrogenic action of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine. HCl (DPPE), a novel intracellular histamine antagonist and selective antiestrogen binding site ligand. J Reprod Fert 1990 ; 89: 59-67.
16. Brandes LJ, Queen GM, LaBella FS N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (DPPE), a chemopotentiating and cytoprotective agent in clinical trials: Interaction with histamine at cytochrome P450 3A4 and other isozymes that metabolize antineoplastic drugs. Cancer Chemother Pharmacol 2000 ; 45 ; 298-304.
17. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 1999 ; 37: 485-505.
18. Katoh M., Nakajima M., Yamazaki H., Yokoi T. Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur J Pharm Sci 2001 ; 12: 505-13.
19. Ling V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 1997 ; 40 (Suppl): S3-8.
20. Menendez AT, Raventos-Suarez C., Fairchild C., et al. Mechanism of action of DPPE, a chemosensitizing agent. Proc Amer Assoc Cancer Res 1998 ; 39: 3462 (abstract).
21. Kroeger EA, Brandes LJ Evidence that tamoxifen is a histamine antagonist. Biochem Biophys Res Commun 1985 ; 134: 750-5.
22. Brandes LJ, Bogdanovic RP, Cawker MD, LaBella FS Histamine and growth: interaction of antiestrogen binding site ligands with a novel histamine site that may be associated with calcium channels. Cancer Res 1987 ; 47: 4025-31.
23. LaBella FS, Brandes LJ Enhancement of tumor growth by drugs with some common molecular actions. Mol Carcinogen 1996 ; 16: 68-76.
24. Kahlson G., Rosengren E. Histamine formation as related to growth and protein synthesis. In: Biogenic Amines as Physiological Regulators (Blum JJ, Ed.) Englewood-Cliffs NJ, Prentice-Hall 1970 ; 223-38.
25. Nebert DW Proposed role of drug-metabolizing enzymes: Regulation of steady state levels of the ligands that affect growth, homeostasis, differentiation and neuroendocrine functions. Mol Endocrinol 1991 ; 5: 1204-14.
26. Reiger MA, Ebner R., Bell DR, Kiessling A., et al. Identification of a novel mammary-restricted cytochrome P450, CYP4Z1, with overexpression in breast carcinoma. Cancer Res 2004 ; 64: 2357-64.
27. Brandes LJ, Queem GM, LaBella FS Displacement of histamine from liver cells and cell components by ligands for cytochromes P450. J Cell Biochem 2002 ; 85: 820-4.
28. Brandes LJ, LaBella FS, Warrington RC Increased therapeutic index of antineoplastic drugs in combination with intracellular histamine antagonists. J Natl Cancer Inst 1991 ; 18: 1329-36.
29. Brandes LJ, Beecroft WA, Hogg GR Stimulation of in vivo tumor growth and phorbol ester-induced inflammation by N,N-diethyl-2-[4-(phenylmethyl) phenoxy] ethanamine. HCl, a potent ligand for intracellular histamine receptors. Biochem Biophys Res Commun 1991 ; 179: 1297-1304.
30. Warrington RC A novel approach for improvong the efficacy of experimental cancer chemotherapy using combinations of anticancer drugs and L-histidinol. Anticancer Res 1986 ; 6: 451-64.
31. Moya-Garcia AA, Medina MA, Sanchez-Jimenez F. Mammalian histidine decarboxylase: from structure to function. Bioessays 2005 ; 27: 57-63.
32. Glavin GB, Gerrard JM Characterization of the gastro-protective effects of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine. HCl, a non-H1, non-H2 histamine antagonist. Digestion 1990 ; 47: 143-8.
33. Brandes LJ, Simons KJ, Bracken SP, Warrington RC Results of a clinical trial in humans with refractory cancer of the intracellular histamine antagonist, N,N-diethyl-2-[4(phenylmethyl) phenoxy] ethanamine in combination with various single antineoplastic agents. J Clin Oncol 1998 ; 12: 1281-90.
34. Warrington RC, Fang WD Reversal of the multidrug-resistant phenotype of Chinese hamster ovary cells by L-histidinol. J Natl Cancer Inst 1989 ; 81: 798-803.
35. Rolland PH, Martin PM, Jacquemier J., Rolland AM, Toga M. Prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst 1980 ; 64: 1061-70.
36. Honn KV, Tang DG, Gao IA, et al. 12-Lipoxygenases and 12(S)-HETE: role in cancer metastasis. Cancer Metastasis Rev 1994 ; 13: 365-96.
37. Tong W. -G, Ding, X-Z., Adrian TE The mechanisms of lioxygenase inhibitor-induced apoptosis in human breast cancer cells. Biochem Biophys Res Commun 2002 ; 296: 942-8.
38. Brandes LJ, Bracken SP, Ramsey EW N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine. HCl in combination with cyclophosphamide: an active low toxicity for metastatic hormonally unresponsive prostate cancer. J Clin Oncol 1995 ; 13: 1398-403.